866-997-4948(US-Canada Toll Free)

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Nov 2017

Category :

Pharmaceutical

No. of Pages : 49 Pages

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H2 2017

Summary

According to the recently published report 'T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H2 2017'; T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) pipeline Target constitutes close to 8 molecules. Out of which approximately 8 molecules are developed by Companies.

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - CD28 is a proteins expressed on T cells. It co-stimulates signals required for T cell activation and survival. It enhances the production of IL4 and IL10 in T-cells in conjunction with TCR/CD3 ligation and CD40L co-stimulation.

The report 'T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H2 2017' outlays comprehensive information on the T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 2 and 2 respectively. Report covers products from therapy areas Immunology, Oncology, Central Nervous System, Dermatology, Genito Urinary System And Sex Hormones, Musculoskeletal Disorders, Ophthalmology and Toxicology which include indications Graft Versus Host Disease (GVHD), Rheumatoid Arthritis, Systemic Lupus Erythematosus, Acute Renal Failure (ARF) (Acute Kidney Injury), Arthritis, B-Cell Chronic Lymphocytic Leukemia, Encephalomyelitis, Gastrointestinal Radiation Toxicity, Hypersensitivity, Kidney Transplant Rejection, Multiple Sclerosis, Plaque Psoriasis (Psoriasis Vulgaris), Psoriasis, Skin And Soft Tissue Infections, Solid Tumor, Stem Cell Transplantation and Uveitis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)
- The report reviews T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics and enlists all their major and minor projects
- The report assesses T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Overview 6
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Therapeutics Development 7
Products under Development by Stage of Development 7
Products under Development by Therapy Area 8
Products under Development by Indication 9
Products under Development by Companies 10
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Therapeutics Assessment 13
Assessment by Mechanism of Action 13
Assessment by Route of Administration 15
Assessment by Molecule Type 17
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Companies Involved in Therapeutics Development 19
Atox Bio Ltd 19
Bristol-Myers Squibb Co 19
Five Prime Therapeutics Inc 20
Johnson & Johnson 20
TheraMAB LLC 21
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Drug Profiles 22
ALPN-101 - Drug Profile 22
Product Description 22
Mechanism Of Action 22
R&D Progress 22
FPT-155 - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
FR-104 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
lulizumab pegol - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
Monoclonal Antibody to Agonize CD278 and CD28 for Oncology - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
Recombinant Protein to Agonize CD278 and CD28 for Oncology - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
reltecimod sodium - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
TAB-08 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Dormant Products 37
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Discontinued Products 38
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Product Development Milestones 39
Featured News & Press Releases 39
Nov 06, 2017: Alpine Immune Sciences Presents ALPN-101 Program Data Demonstrating Potent Preclinical Activity in Arthritis and Inflammation 39
Oct 30, 2017: Five Prime Therapeutics Presents Preclinical Data Demonstrating Potent Anti-Tumor Activity with FPT155 40
Oct 19, 2017: OSE Immunotherapeutics Publishes New Data on FR104, CD28-Antagonist Immunotherapy 40
Oct 18, 2017: Five Prime to Present Preclinical Data on FPT155 at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 41
Sep 25, 2017: Atox Bio Awarded Next Milestone-based Option by BARDA to Support Continued Development of Reltecimod for Necrotizing Soft Tissue Infections 41
Sep 20, 2017: Alpine Immune Sciences Announces Poster Presentation at 2017 ACR/ARHP Annual Meeting 42
Jun 14, 2017: Alpine Immune Sciences Announces Presentation of Preclinical Data Showing Potency of Its First-Generation Dual ICOS and CD28 Antagonist vIgDs in an Animal Model 42
May 23, 2017: Atox Bios Reltecimod Passes Futility Analysis in Phase 3 ACCUTE Study; Trial Continues as Planned 43
Nov 17, 2016: OSE Immunotherapeutics announces the online publication of positive Phase 1 clinical results with FR104 in the Journal of Immunology 43
Nov 03, 2016: Atox Bio Announces Independent Safety Monitoring Committee Recommendation to Continue Phase 3 Study Of AB103 In Necrotizing Soft Tissue Infections 44
Jun 15, 2016: Atox Bio Awarded Next Milestone-based Option by BARDA to Support Development of AB103 for Necrotizing Soft Tissue Infections 44
Dec 07, 2015: Atox Bio Enrolls First Patient in Phase 3 Study of Potential Treatment for Necrotizing Soft Tissue Infection (Flesh Eating Bacteria) 44
Jul 09, 2015: Effimune launches Phase I clinical trial on immune system regulation control 45
Apr 15, 2015: Effimune obtains regulatory approval for Phase I clinical trial in humans of its new immunomodulator FR104 46
Feb 12, 2015: Two major scientific articles validate Effimunes drug candidate and reinforce the proof of concept of the technology aimed at regulating the immune system 46
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 48
Disclaimer 49

List of Tables
Number of Products under Development by Stage of Development, H2 2017 7
Number of Products under Development by Therapy Areas, H2 2017 8
Number of Products under Development by Indication, H2 2017 9
Number of Products under Development by Companies, H2 2017 10
Products under Development by Companies, H2 2017 11
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 12
Number of Products by Stage and Mechanism of Actions, H2 2017 14
Number of Products by Stage and Route of Administration, H2 2017 16
Number of Products by Stage and Molecule Type, H2 2017 18
Pipeline by Atox Bio Ltd, H2 2017 19
Pipeline by Bristol-Myers Squibb Co, H2 2017 19
Pipeline by Five Prime Therapeutics Inc, H2 2017 20
Pipeline by Johnson & Johnson, H2 2017 21
Pipeline by TheraMAB LLC, H2 2017 21
Dormant Projects, H2 2017 37
Discontinued Products, H2 2017 38

List of Figures
Number of Products under Development by Stage of Development, H2 2017 7
Number of Products under Development by Therapy Areas, H2 2017 8
Number of Products under Development by Top 10 Indications, H2 2017 9
Number of Products by Mechanism of Actions, H2 2017 13
Number of Products by Stage and Mechanism of Actions, H2 2017 13
Number of Products by Routes of Administration, H2 2017 15
Number of Products by Stage and Routes of Administration, H2 2017 15
Number of Products by Molecule Types, H2 2017 17
Number of Products by Stage and Molecule Types, H2 2017 17

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *